TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children of both sexes, ranging in age from 4 to 17 years~* History of seasonal allergic rhinitis, mild, moderate or severe, defined according to the ARIA guidelines in 2010, documented by recurrent episodes in the previous year and confirmed by a positive skin test results~* Written informed consent from at least one parent or a legal representative~Exclusion Criteria:~* Lack of informed consent in writing by at least one parent or a legal representative~* Concomitant disorders, such as infection of the upper (sinusitis, etc..) or lower respiratory tract, nasal surgery in the last year, abnormalities of the respiratory tract, immune diseases~* Use of antihistamines, nasal or systemic corticosteroids, leukotriene modifiers, cromolyn sodium, in the last six weeks

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol nasal spray (Type: ACTIVE_COMPARATOR): 2 sprays per nostril 3 times a day for a period of two months
- Placebo (Type: PLACEBO_COMPARATOR): 2 sprays per nostril 3 times a day for a period of two months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anesthesia and Lymphocytes Apoptosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male adults~* aged 18-80 yr~* undergoing elective OPCAB surgery containing left anterior descending artery bypass~Exclusion Criteria:~* a previous unusual response to any of the experimental anesthetics~* severe cardiac dysrhythmias or ejection fraction below 30%~* hemodynamic instability~* previous surgical coronary artery repair~* anemia, abnormal leukocytes or coagulopathy~* severe hypertension~* severe hepatic (albumin\<30g,ascites), renal (serum creatinine greater than 2.0 mg/dl) or pulmonary (preoperative pulmonary function tests moderate-severe) dysfunctions~* concomitant surgical procedures and psychiatric disorders~* Insulin-dependent diabetics

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: EXPERIMENTAL): None
- Propofol (Type: EXPERIMENTAL): None
- Combine of sevoflurane and propofol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* MDD with a HAM-D score of \> 21 and \> 1 on Item 1~Exclusion Criteria:~* Axis I disorder in last 6 months~* Axis II disorder causing significant impact~* Current depressive episode \> 12 months or \< 4 weeks~* No response of current episode to \> 6 weeks treatment with 2 or more classes of antidepressant medication~* Substance abuse or dependence in last 6 months~* Significant medical illness~* Conditions that may alter study drug metabolism~* Significant suicide or homicide risk~* HAM-D Item 3 score \> 2~* Suicide attempt in the last 6 months~* Lab or physical exam abnormalities~* CYP34A inhibitors in last 2 weeks~* Active psychotherapy (not supportive) unless ongoing for \> 3 months~* Antipsychotic, antidepressant, or mood stabilizer in last 7 days (28 days for fluoxetine), MAOI or anxiolytic in last 14 days, or deport antipsychotic within 2 dosing intervals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine XR 50mg (Type: EXPERIMENTAL): Quetiapine XR 50mg OD for 6 weeks
- Placebo 1 (Type: PLACEBO_COMPARATOR): Placebo OD for 6 weeks
- Quetiapine XR 150-300mg (Type: EXPERIMENTAL): Quetiapine XR 150-300mg OD for 6 weeks
- Placebo 2 (Type: PLACEBO_COMPARATOR): Placebo OD for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 12 years of age and older~* Must be in generally good health~* Must meet minimum symptom requirements, as specified in protocol~* Must be willing and able to provide informed consent and participate in all study procedures~* 2-year history of PAR~* Positive skin test to cockroach, dust mite, mold or cat/dog dander~Exclusion Criteria:~* On nasal examination, presence of any nasal mucosal erosion, nasal ulceration or nasal septal perforation at the screening or randomization visit~* Nasal diseases likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, significant polyposis or nasal structural abnormalities~* Nasal surgery or sinus surgery within the previous year~* The use of any investigational drug within 30 days~* Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose~* Women who are pregnant or nursing~* Women of child-bearing potential who are not abstinent and not practicing a medically acceptable method of contraception~* Respiratory tract infection within 2 weeks of screening~* Respiratory tract infections requiring oral antibiotic treatment within 2 weeks of screening~* Patients with asthma with the exception of mild, intermittent~* Significant pulmonary disease including COPD~* Patients with arrhythmia~* Patients with a known history of alcohol or drug abuse~* Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor may significantly alter the absorption, distribution, metabolism or excretion of study drug.~* Clinically relevant abnormal physical findings within one week of randomization~* Overnight abscences from home for more than 3 nights~* Employees of the research center or private practice and family members are excluded~* Patients who received prohibited medications within specified timepoints in protocol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): 0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
- 3 (Type: EXPERIMENTAL): 0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Criteria:~* No active or metastatic cancer within the past 6 months~* Scheduled to undergo colonoscopy for colonic neoplasia surveillance~* Hemoglobin \>= 12.0 g/dL~* Platelet count \>= 120,000/mm\^3~* AST or ALT =\< 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase =\< 1.5 times ULN~* Bilirubin =\< 1.5 times ULN~* BUN =\< 40 mg/dL~* Glomerular filtration rate \>= 45 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No coagulopathy~* No anemia~* No history of peptic ulcer disease or gastrointestinal hemorrhage~* No history of cerebrovascular accident~* No uncontrolled hypertension~* No history of intolerance or allergy to aspirin or to NSAIDs~* No liver disease as manifested by signs or symptoms of cirrhosis~* No endoscopic or radiographic evidence of portal hypertension~* No active colitis by endoscopy~* No history of inflammatory bowel disease~* No requirement for aspirin as medical therapy (i.e., post-myocardial infarction or transient ischemic attack)~* No untreated helicobacter pylori infection~* History of significant colonic neoplasia, defined as 1 of the following:~  * Adenoma within the past 6 years~ * Colorectal cancer within the past 6 years~ * Known adenoma on present exam~ * Histologically confirmed polyps seen on imaging~* INR =\< 1.5~* At least 6 months since prior cancer treatment~* No other concurrent acetylsalicylic acid (aspirin)-containing products or non-steroidal anti-inflammatory drugs (NSAIDs)~* No concurrent systemic corticosteroids~* No other concurrent anticoagulants or antiplatelet agents~* No concurrent investigational drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral acetylsalicylic acid (aspirin) once daily.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be of outpatient status at Visit 1 and through Visit 2~* Patients must be 18 through 65 years of age at Visit 1~* Patients must meet all of the DSM-IV-TR General Diagnostic Criteria for a Personality Disorder AND Patients must meet DSM-IV-TR diagnostic criteria for BPD as determined by the DIPD-IV, confirmed by a psychiatrist with training in the evaluation and assessment of BPD.~* The symptom severity as assessed by the total score of the ZAN-BPD, confirmed by a psychiatrist with training in the evaluation and assessment of BPD, must be greater than or equal to 9 at Visit 2.~* Female patients of childbearing potential must test negative for pregnancy and must be using medically accepted means of contraception throughout the study. Use of any oral or injectable contraception must be initiated prior to Visit 2.~Exclusion Criteria:~* Investigators, study site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.~* Persons employed by Lilly (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at a Lilly facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted~* Have previously participated (have been randomized) or withdrawn from this study or any other Lilly sponsored study investigating olanzapine.~* Have had previous treatment with olanzapine unless, in the opinion of the investigator, the patient's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of olanzapine was confounded by concomitant medication.~* Female patients who are either pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with knee OA as determined by ACR criteria: Knee pain and radiographic osteophytes and at least 1 of the following 2 items: Morning stiffness 30 minutes, Crepitus on motion, a VAS pain score of ≥ 30 mm for index knee at screening,~Exclusion Criteria:~* Weight of \> 125 kg, Inflammatory arthropathy including secondary OA (eg, degenerative arthritis in patients with rheumatoid arthritis) as confirmed by a rheumatologist or investigator, Diagnosis of a condition other than knee OA that, in the investigator's opinion, may cause or affect pain or pain assessment in the index knee; these conditions may include but are not limited to radiculopathy or neuropathy, vasculopathy, fibromyalgia or active depression, Subjects taking neuromodulatory agents (antiepileptics or antidepressants) used as analgesic therapy for neuropathic pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AMG 403 (Type: EXPERIMENTAL): AMG 403 administered as subcutaneous doses
- Placebo (Type: PLACEBO_COMPARATOR): No active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Education Through Pharmacists and Senior Centers (VEPSC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥50;~* Can attend a 2-hour session (though both PHARM and PEER entail 60 minutes of intervention, an additional hour is needed to allow for informed consent and data collection);~* Speak and read English at ≥4th grade level as determined by a brief reading passage;~* Cognitively intact as evidenced by an Abbreviated Mental Status Test score ≥7.~Exclusion Criteria:~* Failure to meet inclusion criteria~* Failure to give informed consent to participate in the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pharmacist-led Intervention (PHARM) (Type: ACTIVE_COMPARATOR): In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
- Peer-led Intervention (PEER) (Type: EXPERIMENTAL): A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: UH3 Pragmatic Suicide Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~We propose to include all patients at the participating sites who:~* Complete PHQ questionnaire and respond to item 9 (regarding thoughts of death or self-harm) more than half the days or nearly every day~* Are currently enrolled in one of the four participating health systems~* Are age 18 or older~* Recent use of Epic Secure Messaging~Exclusion Criteria:~* Recorded diagnosis of dementia or developmental delay~* Previously invited to participate in the UH2 pilot trial~* Non-English speaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Care Management (Type: EXPERIMENTAL): The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
- Skills Training (Type: EXPERIMENTAL): The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
- Usual Care (Type: ACTIVE_COMPARATOR): Those assigned to the Usual Care group will not be approached or contacted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects 18 years of age and older.~2. Subject meets the ICHD (International Classification of Headache Disorders)-3 (2018) diagnostic criteria for Migraine with or without aura.~3. Subject reports 1-6 Migraine attacks per month; other headaches no more than 6 days per month.~4. Subject is willing to and capable of complying with the specified study requirements, provided written Informed Consent, can complete the electronic diaries, and can be contacted by telephone.~Exclusion Criteria:~1. Subject having received Botox treatment in the head region in the prior 3 months.~2. Subject having received supraorbital or occipital nerve blocks in the prior month.~3. Past 6 months of chronic migraine, New Daily Persistent Headache, and chronic tension-type headache per ICHD-3 (2018) diagnostic criteria.~4. Current medication overuse headache.~5. Use of opioid medications in the prior 1 month.~6. Use of barbiturates in the prior 1 month.~7. Subject has \>10 headache days per month~8. Implanted metal/shrapnel or electrical devices in the head (not including dental implants), a cardiac pacemaker or an implanted or wearable defibrillator.~9. Received parenteral infusions for migraine within the previous 2 weeks.~10. Subject has known uncontrolled epilepsy.~11. History of neurosurgical interventions~12. Subject with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.~13. Current drug abuse or alcoholism.~14. Subject is participating in any other clinical study.~15. Skin lesion or inflammation at the region of the stimulating electrodes.~16. Personality or somatoform disorder.~17. Pregnancy or Lactation.~18. Women with child bearing potential without medically acceptable method of contraception (NOTE: Females of child bearing potential must have a negative pregnancy test).~19. Documented history of cerebrovascular event.~20. Subject with recent brain or facial trauma (occurred less than 3 months prior to this study).~21. Subject participated in a previous study with the Relivion device.~22. The subject does not have the basic cognitive and motor skills needed to operate a smartphone.~23. Subject with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters~24. Subject with other significant pain problem that in the opinion of the investigator may confound the study assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Relivion Active device
- Sham (Type: SHAM_COMPARATOR): Relivion Sham device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient who presents with at least one serious skin or soft tissue infection requiring incision and drainage at an affiliated institution or clinic in the St. Louis metropolitan area~Exclusion Criteria:~* Patients with permanent indwelling catheters or percutaneous medical devices~* Patients with a history of dialysis treatments, long term care facility admission, or presents with a surgical wound infection within the past year~* Patients who are pregnant

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Hygiene Education (Type: ACTIVE_COMPARATOR): Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)
- 2: Hygiene education + mupirocin (Type: ACTIVE_COMPARATOR): Application of mupirocin in the nasal mucosa alone
- Education + mupirocin + chlorhexidine (Type: ACTIVE_COMPARATOR): A combination of nasal application of mupirocin and chlorhexidine showers
- 4: Education + mupirocin + bleach baths (Type: ACTIVE_COMPARATOR): A combination of nasal application of mupirocin and bathing in dilute bleach water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete